{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":23,"n_cols":5,"rows_kept":23,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[14,2,14,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910829981303321"]
[null,null,"Autore",null,"Gholamrezanezhad Ali"]
[null,null,"Titolo",null,"Coronavirus disease 2019 (COVID-19) : a clinical guide / / Ali Gholamrezanezhad and Michael P. Dube"]
[null,null,"Pubbl/distr/stampa",null,"Hoboken, NJ : , : John Wiley & Sons, Inc., , [2023]"]
[{"$nulls":4},"©2023"]
[null,null,"ISBN",null,"1-119-78974-5"]
[{"$nulls":4},"1-119-78972-9"]
[null,null,"Descrizione fisica",null,"1 online resource (701 pages)"]
[null,null,"Disciplina",null,"362.1962414"]
[null,null,"Soggetti",null,"COVID-19 (Disease)"]
[{"$nulls":4},"COVID-19 (Disease) - Prevention"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Cover -- Title Page -- Copyright Page -- Contents -- List of Contributors -- Preface -- Chapter 1 COVID-19: Epidemiology -- Origin -- Animal Host -- Infectivity and Incubation -- Modes of Transmission -- Overview -- Respiratory Droplets -- Aerosolization -- Direct Surface Contact and Fomites -- Fecal-Oral -- Bloodborne -- Semen and Vaginal Secretions -- Asymptomatic Transmission -- Virulence and Mortality -- Case Fatality Rate -- Serial Interval -- Reproduction Number/Reproduction Ratio -- Excess Mortality -- Demographics -- Overview -- Age -- Sex -- Race and Ethnicity -- Disease Prevention -- Vaccinations -- Personal Protective Equipment: Respirators and Masks -- Physical Distancing -- Hand and Surface Sanitation -- Adequate Ventilation of Indoor Spaces -- Use of Outdoor Spaces -- Global Impacts -- Distribution -- International Response -- Future Outbreaks -- Conclusions -- References -- Chapter 2 COVID-19: Virology -- Coronaviruses -- Taxonomy -- Morphology -- Nucleic Acid -- Antigenicity -- SARS-CoV-2 -- Morphology and Nucleic Acid -- Spike Protein -- Origin -- Viral Transmission -- Variants -- References -- Chapter 3 COVID-19: Laboratory/Serologic Diagnostics -- Molecular Diagnostics for COVID-19 -- Nucleic Acid Amplification Testing -- RT-qPCR -- RT-LAMP -- CRISPR-Based Techniques -- Sequencing Techniques -- Antigen Testing -- Viral Culture -- Antibody Testing for COVID-19 -- Principles of Antibody Testing -- Antibody Assays for SARS-CoV-2 -- Assay Target Selection -- Binding Assays -- "]
[{"$nulls":4},"Neutralization Assays -- Antibody Assay Sensitivity and Specificity -- Humoral Response to SARS-CoV-2 Infection -- Kinetics of Antibody Response -- Antibody Response and Disease Severity -- Duration of Immunity -- Current and Potential Applications of Antibody-Based Tests in SARS-CoV-2 -- Management of Individual Disease and Sequelae Monitoring."]
[{"$nulls":4},"Contact Tracing -- Vaccine Efficacy -- Conclusions and Future Directions -- References -- Chapter 4 COVID-19: Radiologic Diagnosis -- Current Guidelines on When to Image -- Fleischner Society -- World Health Organization -- Practical Points -- Technical Considerations to Limit Spread While Imaging -- Chest Radiography -- Cross-Sectional Imaging -- Ultrasound -- Imaging by Modality -- X-Ray -- Computed Tomography -- Ultrasound -- PET -- MRI -- Guidelines for Reporting -- RSNA -- COVID-19 Reporting and Data System -- COVID-19 Imaging Reporting and Data System -- References -- Chapter 5 COVID-19: Pathology Perspective -- Gross and Histopathologic Findings in the Respiratory System -- Gross and Histopathologic Findings in the Cardiovascular System -- Histopathologic Findings in Kidney -- Histopathologic Findings in the Gastrointestinal Tract and Liver -- Histopathologic Findings in Brain -- Histopathologic Findings in Skin -- References -- Chapter 6 COVID-19: Immunology -- Anatomic Progression of COVID-19 -- Adaptive Immune Response in the Nasal Passages and the Lungs -- Immune Response to Immunization -- Immune Correlates of Protection from Infection -- Decline in Vaccine-Induced Immune Responses over Time -- Immune Consequences of Virologic Dissemination -- Autoantibodies Against Type I IFN -- Viral Evasion -- Immune Dysregulation -- Antibody-Dependent Cellular Cytotoxicity -- Cytokine Storm -- Conclusions -- Acknowledgments -- References -- Chapter 7 COVID-19: Presentation and Symptomatology -- Pulmonary Manifestations of COVID-19 -- Atypical Acute Respiratory Distress Syndrome -- Otolaryngologic Manifestations of COVID-19 -- Sense of Smell -- Voice Disorders -- Hearing, Tinnitus, and Facial Nerve -- Gastrointestinal Manifestation of COVID-19 -- Coronavirus and Pregnancy -- Physiologic Changes and Effect of SARS-CoV-2 Infection."]
[{"$nulls":4},"General Symptoms of COVID-19 in Obstetric Patients -- Impact of COVID-19 on Gestation: Maternal and Neonatal Outcomes -- Vertical Transmission and Possible Fetal Complications -- COVID-19 and Delivery -- Breastfeeding -- Vaccination -- Urologic Manifestations of COVID-19 -- Kidneys -- Genital and Lower Urinary Tract Infection -- Disorders of Genital Organ Function -- Infertility -- References -- Chapter 8 COVID-19: Risk Stratification -- Potential Biomarkers for COVID-19 Detection, Severity, and Mortality -- Host Risk Factors for COVID-19 -- ABO Blood Type as an Additional Risk Factor -- ABO Blood Group and Rh Factor -- Association of Blood Group with Viral Respiratory Diseases -- Association of Blood Type with Higher Susceptibility to COVID-19 Infection and Outcomes -- Genetic Association and Underlying Molecular Mechanisms -- ML Methods for X-Ray and CT Image Classification and Prediction -- References -- Chapter 9 COVID-19: Outpatient Management in Adults -- Potential Conflicts of Interest -- Initial Diagnosis -- Prognosis and Choice of Admission Versus Outpatient Management -- Home Monitoring -- Telehealth Diagnosis and Follow-up -- Pulse Oximetry Monitoring -- Post-Hospital Discharge Care -- General Management Issues -- Isolation -- Hydration and Nutrition -- Continuation of Ongoing Therapies -- Nutritional Supplements -- Anticoagulation -- Use of Home Supplemental Oxygen -- Antivirals and Anti-inflammatory Treatments -- Anti-SARS-CoV-2 mAbs -- Selection of Outpatients "]
[{"$nulls":4},"to Receive Anti-SARS-CoV-2 mAbs -- Bamlanivimab Plus Etesevimab -- Casirivimab Plus Imdevimab -- Sotrovimab -- Bebtelovimab -- Side Effects of Anti-SARS-CoV-2 mAbs -- Distribution of mAbs -- Oral Antivirals -- Molnupiravir -- Nirmatrelvir (PF-07321332)/Ritonavir -- Outpatient Anti-inflammatory Interventions -- Inhaled Budesonide -- Fluvoxamine -- Dexamethasone."]
[{"$nulls":4},"Drugs That Are Not Recommended for Outpatient Use -- Janus Kinase Inhibitors/Anti-IL-6 Therapies -- Chloroquine and Hydroxychloroquine -- Ivermectin -- Azithromycin -- Lopinavir/Ritonavir -- Convalescent Plasma -- Colchicine -- Summary -- References -- Chapter 10 COVID-19: Inpatient Management -- Respiratory Support for Hospitalized Patients with COVID-19 -- Noninvasive Respiratory Support -- Prone Positioning in Awake Patients -- Caring for the Critically Ill Patient with COVID-19 -- Practical Considerations for Intubating Patients -- Mechanical Ventilation of Patients with COVID-19 -- Rescue Therapies for Refractory Hypoxemia of Ventilated Patients -- Pharmacologic Therapies for Hospitalized Patients with COVID-19 -- Use of Antivirals in Patients Hospitalized for COVID-19 -- Anti-inflammatory Therapies for Hospitalized Patients with COVID-19 -- Therapies that Have No Benefit in Hospitalized Patients with COVID-19 -- Extrapulmonary Disease in Acutely Ill Patients with COVID-19 -- Thromboembolic Disease -- Cardiac Complications -- Renal Complications -- Infectious Complications -- Performing Aerosol-Generating Procedures in Patients with COVID-19 -- Bronchoscopy in COVID-19 -- Tracheostomy in Patients with COVID-19 -- Cardiopulmonary Resuscitation of the Patient with COVID-19 -- Coordinating Patient Placement and Care in COVID-19 Units -- Increasing ICU Capacity -- Additional Management Considerations -- References -- Chapter 11 COVID-19: ICU and Critical Care Management -- Epidemiology of Critically Ill Patients with COVID-19 Pneumonia -- Risk Factors for Severe Disease -- Mortality -- Infection Prevention and Control of COVID-19 in the ICU -- Aerosol-Generating Procedures -- Visitation -- Cardiopulmonary Resuscitation in COVID-19 -- Hemodynamic Support in COVID-19 -- Management of Respiratory Failure from COVID-19 -- Intubation."]
[{"$nulls":4},"Ventilator Management -- Prone Positioning -- Treatment of COVID-19-Associated ARDS with Corticosteroids -- Tocilizumab for Critical COVID-19 Illness -- Extracorporeal Membrane Oxygenation for COVID-19 ARDS -- Venous Thromboembolism and Anticoagulation in COVID-19 -- After the ICU: Challenges for Survivors of COVID-19 Critical Illness -- References -- Chapter 12 COVID-19 in Pediatrics -- Epidemiology -- Epidemiology of Multisystem Inflammatory Syndrome in Children -- Transmission in Children -- Neonatal Transmission -- Breastfeeding -- Clinical Manifestations -- Disease Severity -- Infection in Infants (Age &lt -- 1 Year) -- Cutaneous Manifestations -- COVID Toes -- Neurologic Symptoms -- Atypical Clinical Manifestations -- Imaging Findings -- MIS-C Clinical Manifestations -- Post-Acute Sequelae of SARS-CoV-2 (PASC) in Children -- Approach to Diagnosis -- Screening and Diagnosis in Symptomatic Patients -- Screening and Diagnosis in Asymptomatic Patients -- Neonatal Testing -- COVID-Recovered Patients -- Retesting of COVID-Recovered Patients -- Testing of COVID-19 Fully Vaccinated Persons -- MIS-C Diagnosis -- Hyperinflammation in COVID-19 Versus MIS-C -- Management -- Outpatient Management -- Inpatient Management -- Special Populations -- Antiviral Therapy -- Glucocorticoids -- Nonsteroidal Anti-inflammatory Drugs -- Convalescent Plasma -- Adjunctive Therapy -- Kinase Inhibitors -- Superimposed Infections -- Management of MIS-C -- Guidance for Return to Sports After SARS-"]
[{"$nulls":4},"CoV-2 Infection -- Vaccines -- References -- Chapter 13 Pharmacologic Therapeutics for COVID-19 -- Virus Life Cycle -- Drug Development for SARS-CoV-2 -- Immune Responses that Contribute to COVID-19 Pathology -- Challenges to Discover and Deploy Drugs for a New Infectious Agent -- Therapeutic Classes -- Antivirals -- Camostat (Foipan) -- Nafamostat -- Upamostat."]
[{"$nulls":4},"Chloroquine and Hydroxychloroquine."]